PRINT

Mongolia: Support for COVID-19 Vaccine Delivery in Mongolia under the Asia Pacific Vaccine Access Facility

SUMMARY

STATUS
Approved
MEMBER
Mongolia
SECTOR
Public Health
E&S CATEGORY
Category C
PROJECT NUMBER
000519

FINANCING

APPROVED FUNDING
USD21 million
FINANCING TYPE
Sovereign

TIMELINE

CONCEPT REVIEW
May 19, 2021
FINANCING APPROVAL
June 10, 2021

OBJECTIVE

The Project’s objective is to increase availability of the eligible vaccines for the priority population, as defined by the Government of Mongolia in its National Deployment and Vaccination Plan.

DESCRIPTION

The Project is proposed to be supported under the COVID-19 Crisis Recovery Facility (the Facility) of AIIB and co-financed with the Asian Development Bank (ADB) under the ADB’s Asia Pacific Vaccine Access Facility (APVAX).

The Project will provide the Government of Mongolia (GOM) with immediate financing support to purchase safe and effective vaccines against COVID-19 through APVAX. Through providing timely access to eligible COVID-19 vaccines, the Project will help contribute to containment of the pandemic and supporting economic and social recovery in the country.

The GOM has launched its COVID-19 Vaccination Program and developed the National Deployment and Vaccination Plan (NDVP). The NDVP is an integral part of Mongolia's overall national COVID-19 pandemic prevention and response strategic plan. The NDVP ultimately aims to vaccinate 60% of the population. The Project will support the government in direct procurement of APVAX-eligible vaccines from manufacturers as well as international logistics to Mongolia. The Project will support the implementation of the NDVP and contribute to the government's efforts to immunize at least 30% of the population.

ENVIRONMENTAL AND SOCIAL INFORMATION

The loan will be co-financed with ADB as lead co-financier, and the project’s environmental and social (ES) risks and impacts have been assessed in accordance with ADB’s Safeguard Policy Statement (SPS). To ensure a harmonized approach to addressing the ES risks and impacts of the project, and as permitted under AIIB’s Environmental and Social Policy (ESP), ADB’s SPS will apply to the project in lieu of AIIB’s ESP. AIIB has reviewed ADB’s SPS and is satisfied that: (a) it is consistent with AIIB’s Articles of Agreement and materially consistent with the provisions of AIIB’s ESP, including the Environmental and Social Exclusion List (ESEL) and the relevant Environmental and Social Standards (ESSs); and (b) the monitoring procedures that are in place are appropriate for the project.

ADB has categorized the ES risks of the project as Category C for Environment, C for Involuntary Resettlement and C for Indigenous Peoples (which are equivalent to Category C if AIIB’s ESP were applicable) on the basis that no adverse ES impacts are expected. The program is categorized as “some gender elements” by ADB as the project will significantly benefit women and children by providing access to COVID-19 vaccinations.

PROJECT TEAM LEADER

Asian Infrastructure Investment Bank
Guoping Zhang

Senior Investment Officer

guoping.zhang@aiib.org

 

Asian Development Bank
Najibullah Habib

Health Specialist

nhabib@adb.org

BORROWER

Batkhuu Idesh

Director General,
Development Financing Department,
Ministry of Finance

Batkhuu_i@mof.gov.mn

 

IMPLEMENTING ENTITY

Yanjmaa Binderiya

Director of Division of International Cooperation,
Ministry of Health

yanjmaa@moh.gov.mn

 

PROJECT DOCUMENTS

Home Projects Project Summary Project List Project Details Mongolia: Support for COVID-19 Vaccine Delivery in Mongolia under the Asia Pacific Vaccine Access Facility